顶部联系方式

Time of issue:2018-03-12 00:00:00

Have Any Questions?  Mabspace BiosciencesInfo@mabspacebio.com 迈博斯生物0512-86861701

搜索
迈博斯生物

语言切换

Time of issue:2019-11-21 00:00:00
这是描述信息

PIPELINE

>>
Immuno-Oncology

Immuno-Oncology

  • Categories: Pipeline
  • Time of issue:2018-01-24 00:00:00
  • Views:0
Description:
Description:
Information

MabSpace has established a pipeline of therapeutic antibodies targeting various compoents of the tumor microenvironment. The lead asset is a second generation blocking PD-L1 ab with unique pH-dependent antigen binding and recycling properties. To enable combination therapy, MabSpace has developed antibodies targeting angiogeneic receptor VEGFR2, agonist antibody targeting OX40 for enhancing T cell activities and suppressing regulatory T cells, as well as antibody targeting CSF1R for the inhibition of immune suppresiion mediated by tumor associated macrophage. In addition, MabSpace has ongoing projects targeting dendritic cells and other checkpoint inhibitors.

 

迈博斯

Scan the QR code to read on your phone

页脚关于我们

Time of issue:2019-11-23 00:00:00

页脚管道

Time of issue:2019-11-23 00:00:00

页脚新闻

Time of issue:2019-11-23 00:00:00

页脚人力资源

Time of issue:2019-11-23 00:00:00

页脚联系方式

Time of issue:2019-11-23 00:00:00

页脚版权

Time of issue:2019-11-23 00:00:00

Copyright © 2019 Mabspace Biosciences All rights reserved

页脚备案

Time of issue:2019-11-23 00:00:00